Soberlink, a developer of technology solutions for addiction treatment and recovery management, announced on July 15 that the Food and Drug Administration (FDA) has granted its mobile Breathalyzer pre-market clearance for medical use by health providers. Soberlink for the past five years has been developing a protocol for real-time remote monitoring of alcohol use, with assistance from addiction treatment experts.
The Soberlink products allow for convenient sharing of patients' blood alcohol content results with treatment and recovery professionals. Its patented products include Soberlink Cellular, Soberlink Bluetooth and Sober Sky Web Portal.
A news release from Soberlink included this comment from Treatment Research Institute (TRI) founder and board chairman Tom McLellan: “Remote clinical monitoring has been used successfully in the treatment of other chronic diseases such as diabetes and hypertension to monitor key disease progression indicators and has provided the kind of information that healthcare professionals can use to adjust and improve their patients' care. It is about time that we have the same kind of technology to provide personalized, continuing care for alcohol use disorders.”